Carfilzomib, Pomalidomide, and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma
New treatment approaches are needed in multiple myeloma to extend relapse-free intervals and overall survival. In a phase 1/2 trial, the combination of pomalidomide, dexamethasone, and weekly carfilzomib showed impressive efficacy with acceptable tolerability.
Findings from the Connect MM Registry: Changes in Treatment Patterns in Patients with Newly Diagnosed Multiple Myeloma
Pomalidomide and Low-Dose Dexamethasone Following Second-Line Lenalidomide-Based Therapy in Relapsed or Refractory Multiple Myeloma
Recent study findings presented at the ASH 2016 Annual Meeting suggest that pomalidomide and low-dose dexamethasone can be used immediately following lenalidomide-based therapy to treat patients with relapsed/refractory multiple myeloma.
Salvage Use of Ibrutinib After allo-HSCT for B-Cell Malignancies: A Study of the French Cooperative Group for CLL, the French Society for Blood and Marrow Transplantation (SFGM-TC), and the EBMT Chronic Malignancy and Lymphoma Working Parties
Treatment with ibrutinib in patients with chronic lymphocytic leukemia (CLL) or mantle-cell lymphoma who had disease progression following allogeneic stem-cell transplantation resulted in a 77% overall response rate with a predicted 1-year overall survival of 92%.
CLL2-BIG – A Novel Treatment Regimen of Bendamustine Followed by GA101 and Ibrutinib Followed by Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase 2 Trial
In the prospective, open-label, multicenter, phase 2 CLL2-BIG trial, induction treatment with obinutuzumab and ibrutinib followed by maintenance therapy with continuous ibrutinib and obinutuzumab in a heterogeneous CLL population resulted in an overall response rate of 100% and an minimal residual disease–negativity rate of 47% in the peripheral blood, with no major toxicity.
Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in CLL: Results from a Large Multicenter Study of 683 US Patients
In a multicenter, retrospective analysis of 683 patients with chronic lymphocytic leukemia (CLL), relative efficacy and optimal sequencing of ibrutinib (Ibr), idelalisib (Ide), and venetoclax (Ven) were evaluated. Using overall response rate and progression-free survival as clinical end points, Ibr appears superior to Ide in all settings as first choice kinase inhibitor (KI). In the setting of KI failure, an alternate KI or Ven therapy appears superior to chemoimmunotherapy, whereas an alternate KI appears particularly effective in the setting of intolerance to a prior KI. The use of Ven upon Ibr failure may be superior to the use of Ide. These data provide guidance for sequencing of novel agents.
Healthcare utilization of chronic lymphocytic leukemia (CLL) patients who remain on bendamustine-rituximab (BR) is significantly lower than patients who remain on fludarabine, cyclophosphamide, and rituximab (FCR). Patients aged ≥70 years receiving FCR experienced significantly more days of hospitalization, outpatient visits, and emergency department visits than patients of the same age treated with BR, suggesting BR as an effective, safe, and value-based treatment option for elderly CLL patients.
Multicenter Open-Label Phase 2 Study of Ibrutinib in Chronic Graft-versus-Host Disease (cGVHD) After Failure of Corticosteroids
In chronic lymphocytic leukemia patients with chronic graft-versus-host disease (cGVHD) following allogeneic stem-cell transplantation, treatment with ibrutinib resulted in clinically meaningful and durable responses in patients who had failed at least 1 prior treatment for cGVHD, with a sustained overall response rate of 71% for ≥20 weeks.
Using a novel electronic health record database that included nearly 800 chronic lymphocytic leukemia (CLL) patients, recent (2015-2016) treatment patterns in the United States showed a decline in the use of fludarabine-, bendamustine-, and rituximab-containing regimens and a significant increase in the use of obinutuzumab and ibrutinib, either as monotherapy or in combination regimens. The uptick in use of ibrutinib was especially noted in CLL patients with del17p. The increased utilization of newer agents requires further follow-up and analysis to contrast treatment patterns beyond clinical trial data in a real-world setting and a cost-effectiveness analysis.
Page 12 of 14
Results 111 - 120 of 134
Results 111 - 120 of 134